Business Wire

Carbios Doubles Its Number of Granted Patents in Two Years for Its Proprietary Enzymatic Technologies

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006180/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Carbios patent tiles by geographic region (Graphic: Carbios)

Carbios (Euronext Growth Paris: ALCRB) (Paris:ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, has doubled its number of issued patents since the last review published at the end of 20201.

Protection of Carbios’ processes

Carbios (and its subsidiary Carbiolice) currently holds 336 titles worldwide divided into 53 patent families. In 2022, several titles protecting the proprietary PET-degrading enzymes were granted in countries of interest such as the United States and also in Asian countries including Indonesia, South Korea, China, Japan and India. Carbios has also obtained grants within its patent families protecting the biodegradable plastics production process, notably the masterbatch containing the enzyme or its production process.

"Over the past two years, we have mainly focused on strengthening the protection of our PET biorecycling process and its proprietary enzymes," commented Lise LUCCHESI, Director of Intellectual Property at Carbios . "For the coming years, we will continue to consolidate the protection of this process, and that of our PLA biodegradation process, by filing new patent applications. We will also actively follow up on our filed patent applications in order to obtain granted patents."

"Since the beginning of Carbios, the R&D and Intellectual Property departments have worked hand in hand to ensure maximum protection of our enzymes and processes," commented Alain Marty, Chief Scientific Officer at Carbios. "These continued efforts to obtain extensive international protection are crucial to safeguard our innovations and ensure the industrial deployment of our technologies."

Worldwide protection

Carbios is expanding its intellectual property portfolio in regions and countries where there is strong demand for its disruptive technologies (see Fig. 1), notably :

  • in Europe: 40 European titles, which could be granted in the 39 member states of the European Patent Organization
  • in North America: 41 titles in the United States and 23 in Canada
  • in Asia: 152 titles, including 37 in China, 27 in Japan and 24 in India

Carbios also has 14 patent applications that may be extended to other countries or regions of the world in the coming years.

"We are convinced that biological recycling is the most efficient and circular solution to degrade plastics," stated Emmanuel LADENT, CEO of Carbios . "The protection of our enzymes and processes is at the heart of our work, and we have a dedicated Intellectual Property team within Carbios. From 2023, we will also focus our efforts on protecting innovation related to enzymatic degradation of other polymers."

A dedicated Intellectual Property team

The Intellectual Property team at Carbios includes a Director (who is also a member of the Executive Committee) and two patent engineers specialized in the fields of biotechnology and polymer chemistry, one of whom is a representative before the European Patent Office. The team is supported by two external Intellectual Property consulting firms (Becker & Associés and Franck Tetaz Intellectual Property). Finally, an Intellectual Property Committee reports regularly to Carbios’ Board of Directors.

About Carbios

Established in 2011 by Truffle Capital, Carbios is a green biotech company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recently recognized in a scientific paper published in front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.

In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products. PVH Corp. joined this consortium in January 2023.

The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable at ambient temperatures, even in domestic conditions, integrating enzymes at the heart of the plastic product.

For more information, please visit carbios.com / Twitter: Carbios / LinkedIn: Carbios / Instagram: insidecarbios

Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in France, in Europe, in the United States or in any other country.

In case of discrepancy between the French and the English version of this press release, the French version shall prevail.

1 Cf. press release dated 14 January 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CARBIOS
Melissa Flauraud
Press Relations
melissa.flauraud@carbios.com
Benjamin Audebert
Investor Relations
contact@carbios.com
+33 (0)4 73 86 51 76

Press Relations (France)
Iconic
Marie-Virginie Klein
mvk@iconic-conseil.com
+33 (0)1 44 14 99 96

Press Relations (U.S.)
Rooney Partners
Kate L. Barrette
kbarrette@rooneyco.com
+1 212 223 0561

Press Relations (DACH & UK)
MC Services
Anne Hennecke
carbios@mc-services.eu
+49 (0)211 529 252 22

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM and Scientek Corporation Sign Reseller Agreement to Boost Quantum Computing in Taiwan18.9.2025 11:11:00 EEST | Press release

IQM Quantum Computers and Scientek Corporation, a Taiwan-based reseller of scientific instruments and other high-technology products, today announced the signing of a strategic reseller agreement to accelerate the commercialisation of quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918110284/en/ IQM and Scientek Corporation sign reseller agreement The agreement follows the installation of IQM Spark, the first full-stack superconducting quantum computer at the Taiwan Semiconductor Research Institute (TSRI). Under the reseller agreement, Scientek will sell and promote IQM’s on-premises quantum computers and cloud solutions that meet the evolving needs of universities, research institutions, and enterprises. Combining Scientek's strong market presence and customer-centric approach in Taiwan with IQM’s quantum leadership, the collaboration will help Taiwanese businesses and research institutions to explore a

Acuity Knowledge Partners Acquires Ascent18.9.2025 10:30:00 EEST | Press release

Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc

Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 09:00:00 EEST | Press release

Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the importance of the findings of the POSITIVE study and its unique approach to evaluating the long-term holistic impact of an advanced treatment in patients with moderate-to-severe psoriasis, a condition that profoundly impairs social, psychological, and physical quality of life, impacting overall well-being1. Two‑Year Real‑World Results from POSITIVE The 24-month, multinational, phase IV observational study enrolled 785 adult patients with moderate-to-severe plaque psoriasis across nine European countries

Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 09:00:00 EEST | Press release

Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with confidence. This joint offering provides an end-to-end solution designed to meet evolving regulatory expectations, accelerate adoption

Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 08:00:00 EEST | Press release

Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye